stockrow
Friday 6 November 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
- EPS
- +95.1%
- Free cash flow
- −19.3%
Quarter to June 2026, against a year earlier
8.87
0.14
+1.60%
Follow MBRX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.94 | 1.38 | 1.41 | 1.39 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.96 | 1.31 | 1.18 | 1.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.42 | (0.35) | 0.28 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.53 | 0.48 | 0.50 | 0.55 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(23.44) | (29.64) | (90.64) | (96.82) | |
Cash per Share |
25.57 | 50.03 | 149.97 | 89.85 | |
Shareholders Equity per Share |
40.80 | 73.63 | 253.48 | (360.86) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
40.80 | 73.63 | 253.48 | (360.86) | |
Free Cash Flow |
(6.66) | (6.11) | (5.37) | (7.22) | |
Working Capital |
(0.59) | 3.00 | 2.83 | 2.20 | |
Net Current Asset Value |
(0.78) | 2.78 | 2.57 | (39.39) | |
| Other line items | |||||
Quick Ratio |
0.78 | 1.30 | 1.30 | 1.18 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(23.44) | (29.64) | (90.64) | (96.82) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
8.61 | 7.43 | 6.11 | 5.64 | |
Average Assets |
21.34 | 22.19 | 19.53 | 21.87 | |
Average Common Equity |
2.21 | 7.61 | 13.11 | (9.72) |
Columns are period end dates · fundamentals updated 2 Nov 2026